Inactive Instrument

Seagen Inc.

Equities

SGEN

US81181C1045

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Takeover rumors send Morphosys to high since July 2021 DP
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Biotechnology Select Industry Index CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P TMI Index CI
Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Global BMI Index CI
Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev DJ
Pfizer: dividend increases, stock rebounds CF
Euphoria subsides for Triple-Witching Day Our Logo
ANALYST RECOMMENDATIONS : Adobe, Blackrock, Roblox, Snap, US Bancorp... Our Logo
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5% MT
Seagen Inc.(NasdaqGM:SGEN) dropped from NASDAQ Biotechnology Index CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ-100 Index CI
Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index CI
Pfizer, Inc: A cycle for nothing? Our Logo
Pfizer Completes $43 Billion Acquisition of Seagen MT
Pfizer: Seagen acquisition now complete CF
Seagen Inc. Announces Management Changes CI
Seagen Inc. Announces Cessation of David R. Epstein as Chief Executive Officer CI
Seagen Inc. Announces Cessation of Todd E. Simpson as Chief Financial Officer CI
Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ Composite Index CI
Pfizer Inc. completed the acquisition of Seagen Inc. from Baker/Tisch Investments, L.P, a funds managed by Baker Brothers Investments and others. CI
Pfizer shares sink after it resets 2024 COVID expectations RE
Sector Update: Tech Stocks Rise Late Afternoon MT
Sector Update: Tech Stocks Mixed Wednesday Afternoon MT
Global markets live: BAE Systems, Amazon, Take-Two, Shell, Pfizer... Our Logo
Pfizer shares slide as 2024 revenue outlook underwhelms AN
Chart Seagen Inc.
More charts
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
More about the company
  1. Stock
  2. Equities
  3. Stock Seagen Inc. - Nasdaq
  4. News Seagen Inc.
  5. Seagen : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination to Treat Urothelial Cancer